RecruitingNCT04028531
Understanding Chronic Lymphocytic Leukemia
Sponsor
Dana-Farber Cancer Institute
Enrollment
2,750 participants
Start Date
Sep 29, 1999
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This is an observational study that collects information and samples from patients with chronic lymphocytic leukemia (CLL) — a slow-growing blood cancer — and related conditions, to help researchers better understand how these diseases develop and respond to treatment over time.
**You may be eligible if...**
- You have been diagnosed with chronic lymphocytic leukemia (CLL), monoclonal B-cell lymphocytosis (a precursor condition), or another low-grade lymphoproliferative disorder (a slow-growing blood cell condition)
- You are seen for treatment at Dana-Farber Cancer Institute or elsewhere
**You may NOT be eligible if...**
- There are no formal exclusion criteria listed for this study
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04028531
Related Trials
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902629 locations
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
NCT067929942 locations
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559196 locations
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671115 locations
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872167 locations